GLDN: A Protein Implicated in Neurodegenerative Diseases (G342035)

Target Name: GLDN

NCBI ID: G342035

GLDN

GLDN: A Protein Implicated in Neurodegenerative Diseases

GLDN (Glycophosphorositolylated lung neurotrophic factor) is a protein that is expressed in the nervous system and has been shown to play a role in the development and progression of neurodegenerative diseases. It is also a potential drug target (or biomarker) for a variety of neurological disorders.

GLDN is a transmembrane protein that is expressed in the central and peripheral nervous system. It is composed of four intracellular domains: a extracellular domain, a transmembrane domain, an intracellular domain, and a C-terminal domain. The extracellular domain is the largest and is responsible for the protein's ability to interact with extracellular ligands. The transmembrane domain is responsible for the protein's ability to span the cell membrane and for its role in cell signaling. The intracellular domain is responsible for the protein's ability to interact with intracellular ligands and for its role in intracellular signaling. The C-terminal domain is a unique feature that is found only in GLDN and is responsible for the protein's ability to interact with other proteins.

GLDN has been shown to play a role in a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It is also been shown to be involved in neurodegenerative diseases, such as ALS and multiple sclerosis.

In addition to its role in neurological disorders, GLDN has also been shown to be involved in a variety of other biological processes. For example, GLDN has been shown to play a role in cell signaling, cell migration, and neuroplasticity. It is also involved in the regulation of ion channels and in the production of neurotransmitters, such as dopamine and serotonin.

As a potential drug target, GLDN is being studied for its ability to treat a variety of neurological disorders. For example, GLDN has been shown to be an effective treatment for Alzheimer's disease in animal models. It is also being tested in clinical trials for the treatment of other neurological disorders, including Parkinson's disease and Huntington's disease.

In conclusion, GLDN is a protein that is expressed in the nervous system and has been shown to play a role in the development and progression of neurodegenerative diseases. It is also a potential drug target (or biomarker) for a variety of neurological disorders. Further research is needed to fully understand the role of GLDN in neurological disorders and to develop effective treatments.

Protein Name: Gliomedin

Functions: Ligand for NRCAM and NFASC/neurofascin that plays a role in the formation and maintenance of the nodes of Ranvier on myelinated axons. Mediates interaction between Schwann cell microvilli and axons via its interactions with NRCAM and NFASC. Nodes of Ranvier contain clustered sodium channels that are crucial for the saltatory propagation of action potentials along myelinated axons. During development, nodes of Ranvier are formed by the fusion of two heminodes. Required for normal clustering of sodium channels at heminodes; not required for the formation of mature nodes with normal sodium channel clusters. Required, together with NRCAM, for maintaining NFASC and sodium channel clusters at mature nodes of Ranvier

The "GLDN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLDN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets